<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20261117071824N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-22</date_registration>
      <primary_sponsor>Hajvery University</primary_sponsor>
      <public_title>Effectiveness of Mulligan SNAG, Maitland Mobilization, and Kaltenborn Mobilization at 48 Hours on Pain, Stiffness, Disability, and Lumbar Range of Motion in Adults with Chronic Non-Specific Low Back Pain: A Randomized Clinical Trial</public_title>
      <acronym>SNAGs ROMs NSLBP LBP NPRS RCT</acronym>
      <scientific_title>Effectiveness of Mulligan SNAG, Maitland Mobilization, and Kaltenborn Mobilization at 48 Hours on Pain, Stiffness, Disability, and Lumbar Range of Motion in Adults with Chronic Non-Specific Low Back Pain: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/94921</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This is a three arm, parallel-group randomization clinical trial comparing short term effectiveness of mulligan SNAGs, Maitland mobilization and kaltenborn mobilization in adults with chronic non specific low back pain. Participants will be randomly allocated to one group os three intervention groups. Outcome will be assessed at baseline and 48 hours following intervention, allocation rate will be 1:1:1, Randomization description: This randomized clinical trial includes three parallel treatment groups: Mulligan SNAG, Maitland Mobilization, and Kaltenborn Mobilization, with participants assigned equally to each group (1:1:1). sample size of population is 48, this population will be randomly divided in groups, 16 individuals to each experimental group will be added, Blinding description: This study will be conducted using a double-blind design. Participants will be blinded to their group allocation, and the outcome assessors responsible for collecting and evaluating the study data will also remain blinded to the treatment allocation throughout the study. The interventions will be administered by a separate therapist who will not be involved in outcome assessment or data analysis. Group allocation will remain concealed from the outcome assessors until completion of data collection and analysis.</study_design>
      <phase>2</phase>
      <hc_freetext>Chronic Non Specific Lower Back Pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group A mulligan SNAGs: will get sustained, pain-free glide applied by the therapist while the participant actively moves the lumbar spine in the selected direction. The technique will be stopped if symptoms worsen. Intervention 2: Intervention group B Maitland Mobilization: will get treatment of Passive central and unilateral posteroanterior oscillatory mobilization applied to the lumbar region at Grade III or IV, according to the standardized procedure and the participant’s tolerance. Intervention 3: Intervention group C Kaltenborn mobilization: Sustained, graded traction and translatory mobilization of the lumbar region using a Grade III stretch when clinically appropriate and tolerated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Deidentified individual participant data and research documents related to the randomized controlled trial entitled “Short-Term Effectiveness of Mulligan SNAG, Maitland Mobilization and Kaltenberg Mobilization at 48 Hours on Pain, Stiffness, Disability and Lumbar Range of Motion in Adults with Chronic Nonspecific Low Back Pain” The shared materials may include the study protocol, statistical analysis plan, approved informed consent form, clinical study report, and deidentified participant-level data, including relevant demographic and clinical characteristics and pre- and post-intervention assessment results. No personally identifiable participant information will be shared.

When:
The data and research documents will become available after completion of the study and publication of the primary research results. They will remain available for five years after publication, subject to institutional policies, ethical approval, and applicable data protection requirements.

To whom:
The deidentified data and research documents will be available to qualified researchers, academic investigators, and research institutions for legitimate scientific and academic purposes.

Conditions:
The data and documents may be used for legitimate scientific research, academic purposes, and systematic reviews or meta-analyses. Access will be granted only after review and approval of a reasonable research request. Researchers must ensure participant confidentiality, use the data only for the approved purpose, and comply with applicable ethical and data protection requirements.

Where to obtain:
The data and research documents can be requested from the principal investigator of the study through the contact information provided in the IRCT trial registration record.

How to obtain:
Researchers must submit a written request to the principal investigator describing the research purpose and intended use of the requested data. Requests will be reviewed by the research team and, where required, the relevant ethics committee. Access will be provided only after approval and agreement to maintain confidentiality and comply with data protection requirements. Only deidentified data will be shared.

Comments:
no additional comments</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Barjees Ahmed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hajvery University Euro Campus</address>
        <city>lahore</city>
        <country1>Pakistan</country1>
        <zip>54660</zip>
        <telephone>+92 309 4524200</telephone>
        <email>barjeeskamran@gmail.com</email>
        <affiliation>Hajvery University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dt. Rimsha Tariq</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hajvery University Euro Campus</address>
        <city>lahore</city>
        <country1>Pakistan</country1>
        <zip>54660</zip>
        <telephone>+92 332 8001459</telephone>
        <email>rimshakhan209@gmail.com</email>
        <affiliation>Hajvery University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Chronic non-specific low back pain for ≥12 weeks.
Baseline pain score ≥3/10 on NPRS.
Able to attend baseline and 48-hour assessment.
Age 18–45 years; either sex
Written informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Red flags or suspected serious pathology, including fracture, malignancy, infection, inflammatory spinal disease, or cauda equina syndrome.
Progressive neurological deficit or radiculopathy requiring specialist assessment
Previous lumbar spinal surgery
Pregnancy or contraindication to manual therapy
Manual therapy or structured physiotherapy for low back pain during the previous 4 weeks; or any condition that prevents safe participation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group A mulligan SNAGs: will get sustained, pain-free glide applied by the therapist while the participant actively moves the lumbar spine in the selected direction. The technique will be stopped if symptoms worsen</i_keyword>
      <i_keyword>Intervention group B Maitland Mobilization: will get treatment of Passive central and unilateral posteroanterior oscillatory mobilization applied to the lumbar region at Grade III or IV, according to the standardized procedure and the participant’s tolerance.</i_keyword>
      <i_keyword>Intervention group C Kaltenborn mobilization: Sustained, graded traction and translatory mobilization of the lumbar region using a Grade III stretch when clinically appropriate and tolerated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity will be measured using the 11-point Numeric Pain Rating Scale (NPRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants will rate their average low back pain intensity over the previous 24 hours at baseline and 48 hours after treatment. Higher scores indicate greater pain intensity. Timepoint: Baseline Assessment before the application of treatment, At the completion of interventions (post experimental). Method of measurement: Pain intensity will be measured by NPRS scale by scoring intensity between 0 to 10 at scale.</prim_outcome>
      <prim_outcome>Subjective stiffness will be evaluated using a 100-mm Visual Analog Scale (VAS), consisting of an unmarked horizontal line anchored from "No stiffness" (0 mm) to "Worst imaginable stiffness" (100 mm). Participants will mark their perceived stiffness level along the line, and the distance from the zero anchor was measured in millimeters to yield a continuous score from 0 to 100. Timepoint: Two time measurements will be taken one is at baseline before application of interventions and second one is After the application of treatment. Method of measurement: As patient will choose line on 100 mm visual analogue scale, no of line will be consider as score out of 100.</prim_outcome>
      <prim_outcome>The Oswestry Disability Index (ODI), Version 2.1a, will be used to assess low back pain-related functional disability. It consists of 10 sections, each scored from 0–5, with higher scores indicating greater disability. Assessments will be performed at baseline and 48 hours after treatment. Timepoint: Baseline and post intervention measurements will be taken. Method of measurement: This 10-item questionnaire will measure how much lower back limits a Individual's everyday physical function. It also produces a disability score from 0% with no disability to 100% with maximum disability.</prim_outcome>
      <prim_outcome>Double inclinometer. Timepoint: Baseline and post intervention measurements will be taken. Method of measurement: Lumbar flexion, extension, right lateral flexion, and left lateral flexion measured in degrees.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Myself</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-15</approval_date>
        <contact_name>Allied Health Sciences faculty Hjvery University pakistan</contact_name>
        <contact_address>33 Industrial Area, Gulberg III, Lahore, Pakistan lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-15</approval_date>
        <contact_name>Allied vHealth Science Hajvery University lahore, Pakistan</contact_name>
        <contact_address>33 Industrial Area, Gulberg III, Lahore, Pakistan lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-15</approval_date>
        <contact_name>Allied Health Sciences Department Hajvery University Lahore</contact_name>
        <contact_address>33, Industrial Area, Gulberg III, Lahore, Pakistan lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
